Core Insights - In the first seven months of the year, 600 out of 650 comparable QDII funds saw an increase in net value, representing a 92.31% success rate [1] - The innovation drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top-performing funds achieving returns exceeding 137% [1] - Several QDII funds, particularly those managed by E Fund, reported increases of over 90%, with four funds exceeding 95% returns, all focused on the innovative drug industry [2] Group 1: Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hang Seng Innovation Drug ETF and others, with returns ranging from 100.48% to 87.44%, attributed to the strong performance of the innovation drug sector [3] - The leading QDII funds, such as Huatai-PineBridge and E Fund, have concentrated their investments in key innovative drug companies, including Innovent Biologics and Sinopharm [2][3] Group 2: Fund Management - The fund manager for the top-performing Huatai-PineBridge funds is Zhao Bei, who has been with the company since 2010 and currently leads the healthcare research team [3] - Zhang Wei, the manager of the top-performing Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund, has a background in pharmaceutical research and has held various roles in the industry [1]

Core Insights - In the first four months of this year, 368 out of 650 comparable QDII funds saw an increase in net value, representing approximately 56.6% of the total funds [1] - The top-performing funds were Huatai-PineBridge Hong Kong Advantage Selection Mixed A and C, with returns of 59.43% and 59.19% respectively [1] - The fund manager Zhang Wei believes that the pharmaceutical industry will continue to show good anti-cyclical and technological attributes over the next 2 to 3 years, focusing on innovative drugs and high-barrier leading companies in medical equipment [1] Fund Performance - The second tier of QDII funds includes nine funds with returns between 30% and 35%, such as ICBC New Economy Mixed RMB and USD, and E Fund Gold Theme funds [2] - Specifically, ICBC New Economy Mixed RMB and USD achieved returns of 34.25% and 34.01% respectively, maintaining a high position in innovative drug investments [2] - The top ten holdings for these funds include companies like Kelun Pharmaceutical and Innovent Biologics [2] Gold-Themed Funds - E Fund Gold Theme funds benefited from the rise in gold and gold stocks, with returns of 31.21% to 30.71% [3] - These funds shifted their holdings from gold stocks to gold itself as of March, focusing on gold as the primary asset [3] Declining Funds - A total of 49 QDII funds experienced declines of over 10%, with the largest drop being 16.12%, primarily in oil and gas-related sectors [3] Performance Rankings - The performance rankings for QDII funds show that Huatai-PineBridge Hong Kong Advantage Selection Mixed A and C lead the pack, while several oil and gas-focused funds are at the bottom of the list [4][5]